It's a science about working on the small scale, but it has big promise. Michael Francis of Accelrys looks to the future of nanotechnology
Integrating LIMS with enterprise resource planning software is topical, but Peter Rees found that standardising and centralising are essential first steps
If the trend is towards standardisation, how can LIMS be tailored to fit individual customers? The answer lies with workflows, according to Colin Thurston
Although sometimes their role is overlooked, distributors can add value to scientific software through the technical support they provide. John Murphy talked to Adept Scientific, one of the largest distributors
Felix Grant believes that software can open up the big ideas in mathematics to the wider public, democratising the subject, and making it part of popular culture
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
